您的位置: 首页 » 法律资料网 » 法律法规 »

国家税务总局关于进一步做好所得税收入分享体制改革后征管工作的通知

时间:2024-07-07 09:34:18 来源: 法律资料网 作者:法律资料网 阅读:9243
下载地址: 点击此处下载

国家税务总局关于进一步做好所得税收入分享体制改革后征管工作的通知

国家税务总局


国家税务总局关于进一步做好所得税收入分享体制改革后征管工作的通知

国税发[2002]120号
国家税务总局
2002-9-12


各省、自治区、直辖市和计划单列市国家税务局、地方税务局:

所得税收入分享体制改革实施半年来,各级税务机关讲政治、讲大局、讲团结、讲协作,根据国务院的改革方案和国家税务总局的规定,在所得税征管工作中相互配合,密切合作,使所得税收入分享体制改革得以顺利推进。为进一步做好所得税征收管理工作,确保所得税收入分享体制改革落实到位,现就有关问题通知如下:
一、进一步提高对所得税收入分享体制改革重要意义的认识

国务院决定改革所得税收入分享体制,具有十分重要而深远的政治和经济意义,目的是为了进一步规范中央和地方政府之间的分配关系,建立合理的分配机制,减缓地区间财力差距的扩大,防止重复经济建设,支持西部大开发,促进社会主义市场经济健康发展,逐步实现共同富裕,为国家长治久安打下坚实的基础。各级税务机关一定要从实践“三个代表”、确保国家长治久安和保持我国经济持续、稳定、健康发展的政治经济全局角度,深刻领会国务院战略决策的重大意义,自觉做好所得税收入分享体制改革后的各项工作。要进一步贯彻“加强征管、堵塞漏洞、惩治腐败、清缴欠税”的工作方针,切实采取措施加强所得税征收管理,确保所得税收入分享体制改革的顺利实施,确保所得税各项工作任务的完成。
二、坚决清理纠正越权自定的所得税优惠政策

近年来,一些地区为发展地方经济、吸引投资,在统一政策之外越权自定了不少所得税优惠政策。在我国加入世界贸易组织后,继续这样做不仅不能真正起到吸收投资的作用,而且也不符合依法治税的原则。实施所得税收入分享体制改革后,所得税收入中央、地方共享,地方越权自定所得税优惠政策,还将侵蚀中央收入,削弱所得税收入分享体制改革的作用。另外,国务院领导一再强调,即使是地方收入的部分,各地也无权任意减免。各地税务机关应按照国家税务总局的要求,对地方越权擅自制定的各种企业所得税优惠政策进行认真清理,并立即停止执行。已清理的优惠政策,不得反弹。必须严格按照税法规定的条件和范围执行现行有关优惠政策,国家税务总局将适时组织执法检查,一经发现本通知下发后仍继续执行地方越权制定的所得税优惠政策的情况将予以通报,并按照税收征管法的规定,依法追究直接责任人的行政责任。
三、保持所得税政策的一致性

按照所得税收入分享体制改革后新的所得税征管范围,国税局、地税局必须保持所得税政策的一致性,若执行所得税政策不统一,税基管理不一致,就会人为造成企业的税收负担有轻有重,违反税收的公平原则,增加税务机关征收管理的难度,削弱税务机关执法的权威性。因此,在执行所得税政策上,国税局、地税局要多通气、多协调,尽量取得一致意见。对政策理解分歧较大、难以统一意见的,要及时请示总局解决。税务机关在所得税征管中要严格依法办事,坚持以税法规定为基础,要完善执法责任制。
四、切实加强对核定征收所得税企业的管理

各级税务机关要努力促使企业建账建制,坚持对具备条件的企业实行查账征收。但是,目前我国还有大量中小企业不具备查账征收条件,对这些中小企业,要按照税收征管法和企业所得税核定征税有关办法的规定,进一步规范核定征税的程序和方法,切实加强管理,特别是对税额的核定要坚持民主评议程序,防止由于人为因素造成税负不公;要对随着经营规模扩大、核定标准与企业实际经营情况发生显著变化的核定征税企业,及时调整核定标准或改为据实征收;国税局、地税局要做好核定征税工作的沟通、衔接,绝不允许为争抢管户,竞相压低核定征税的标准,对相同或类似行业、规模、地域的企业,核定的税负要尽可能保证一致。
五、进一步加强协作,切实防止漏管重征

关于所得税收入分享体制改革后的税收征收管理范围问题《国务院关于印发所得税收入分享改革方案的通知》(国发[2001]37号文件)和《国家税务总局关于所得税收入分享体制改革后税收征管范围的通知》(国税发[2002]8号文件)已经做了较为详细的规定。各级税务机关必须严格按上述文件规定划分征管范围,不得争抢或推诿。要按照税收征管法的有关规定,加强与工商行政管理等部门的协调配合,既要防止出现漏征漏管户,也要防止出现国税局、地税局两家重征重管,给纳税人造成不必要的麻烦和负担。对由于企业改革中不断出现新情况,有关部门在新设立企业的登记管理方面掌握的口径不尽一致,造成各地国税局、地税局实际划分征管范围不便的,各级税务机关一定要讲团结、讲大局,本着既坚持原则,又注意沟通协商的精神,具体情况具体分析、具体解决。沟通协商不一致的,要向上级税务机关请示,决不允许在协商未取得一致意见前,单方面对国务院和国家税务总局关于征管范围的规定发文明确解释口径。


Provisions for Drug Insert Sheets and Labels

Commissioner of SFDA


Provisions for Drug Insert Sheets and Labels



(SFDA Decree No.24)

The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.


Shao Mingli
Commissioner of SFDA

March 15, 2006





Provisions for Drug Insert Sheets and Labels


Chapter I General Provisions

Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People’s Republic of China and the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China.

Article 2 The insert sheets and labels of drugs marketed within the territory of the People’s Republic of China shall meet the requirements of the Provisions.

Article 3 Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.

A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.

Article 4 A drug label shall be printed on or affixed to the drug package, and no other written words, audio and/or visual materials or other information are attached to introduce or publicize the product or the enterprise.

An insert sheet shall be attached to the smallest package provided by the drug manufacturer for marketing.

Article 5 The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.

Article 6 In the label or insert sheet, the letters or characters shall be clear and easy to be recognized and the marks shall be clear and distinctive. The label and insert sheet shall have no print faded and shall not be affixed unsteadily. Any addition or modification shall not be made by means of pasting, cutting or altering.

Article 7 Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.

Article 8 With the aim to protect public health and direct the rational use of drugs, drug manufacturers may voluntarily apply to add warnings to drug insert sheets or labels. The State Food and Drug Administration may also request drug manufacturers to add warnings to drug insert sheets or labels.


Chapter II Drug Insert Sheet

Article 9 A drug insert sheet shall include the significant scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The specific format, content and writing requirements of drug insert sheet shall be prescribed and issued by the State Food and Drug Administration.

Article 10 Disease names, pharmaceutical terms, drug names, the names and results of clinical testing in drug insert sheets shall be expressed in professional terms published or standardized by the State. The units of measurement shall conform to the national standards.

Article 11 All the active ingredients or medicinal ingredients of traditional Chinese medicines in a prescription shall be listed in the insert sheet. For injections and non-prescription drugs, all excipients shall be listed as well.

The ingredients or excipients included in a prescription, which may cause severe adverse reaction, shall be specified.

Article 12 A drug manufacturer shall trace the safety and efficacy of its marketed drugs. For any modification to the insert sheet, an application shall be submitted timely.

The State Food and Drug Administration may also require a drug manufacturer to make modification to the insert sheet on the basis of the results of adverse drug reaction monitoring and drug re-evaluation.

Article 13 After the modification to the insert sheet is approved, the drug manufacturer shall inform relevant drug distributors, drug users and other departments of the modified content immediately, and use the modified insert sheet and label timely as required.

Article 14 The insert sheet shall provide full information on adverse drug reaction and indicate the adverse reactions in detail. A drug manufacturer, who fails to timely modify the insert sheet on the basis of the safety and efficacy data of the marketed drug or to fully explain the adverse reaction in the insert sheet, shall be liable for all the consequences arising therefrom.

Article 15 The approval date and the modification date shall be distinctively shown in the insert sheet.


Chapter III Drug Labels

Article 16 Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.

Article 17 The inner label shall bear such drug information as the adopted name in China, indications or functions, strength, dose and usage, production date, batch number, expiry date and manufacturer. If there is no enough space in the package to include all the information mentioned above, the adopted name in China, strength, batch number and expiry date shall be indicated at least.

Article 18 The outer label of a drug shall indicate such information as the adopted name in China, ingredients, description, indications or functions, strength, dose and usage, adverse reactions, contraindications, precautions, storage, production date, batch number, expiry date, approval number and manufacturer. Where indications or functions, dose and usage, adverse reactions, contraindications and precautions cannot be fully noted, main information plus a “See drug insert sheet for details.” notice shall be indicated.

Article 19 The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.

Article 20 The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated.

Article 21 Where one drug produced by a manufacturer has the same drug strength and packaging specification, the content, format and color of its labels must be the same. Where one drug produced by a manufacturer has different drug strengths or packaging specifications, its labels shall be clearly distinguished from one another, or its specifications shall be notably marked in the corresponding specification items.

Where a drug produced by a manufacturer is administrated as prescription drug and non-prescription drug respectively, their packaging colors shall be distinctly different.

Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.

Article 23 The expiry date in the drug label shall appear in the order of year, month and day, with year shown in four digits, month and day in two digits. Its specific format shall be “Valid till XXXX year XX month” or “Valid till XXXX year XX month XX day”. It may be presented with numbers and other symbols as “Valid till XXXX.XX.” or “Valid till XXXX/XX/XX”.

For the preventive biological product, the expiry date shall be labeled according to the registration specifications approved by the State Food and Drug Administration. The expiry date of the biological product for therapeutic use shall be counted from the filling date. For other drugs, the expiry date shall be counted from the production date.

Where the expiry date is labeled to the day, it shall be marked as one day earlier than the actual expiry date; where the expiry date is labeled to the month, it shall be marked as one month earlier than the actual expiry month.


Chapter IV Use of Drug Name and Registered Trademark

Article 24 The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.

Article 25 The adopted name in China shall be conspicuous and prominent, and its typeface, size and color shall be consistent, and meet the following requirements:
(1) For horizontal labels, the adopted name in China shall appear in a prominent position within the area of the upper one-third of the label; for vertical labels, it shall appear in a prominent position within the area of the right one-third of the label;
(2) No such illegible typefaces as cursive characters and seal characters shall be used, and no such format as italics, margining and shading shall be used to modify the typefaces.
(3) The font color of the adopted name in China shall be black or white, in sharp contrast to the light-colored or dark-colored background respectively.
(4) Writing in separate lines shall be avoided unless limited by the packaging size.

Article 26 The trade name of a drug shall not be placed in the same line with the adopted name in China; its typeface and color shall be no more conspicuous than that of the adopted name in China, and its font area per character shall be no bigger than half of that of the adopted name in China.

Article 27 Unregistered trademarks and other drug names unapproved by the State Food and Drug Administration shall not be used in the drug insert sheets and labels.

Where a registered trademark is used in a drug label, it shall be printed in a corner of the label. Where a registered trademark contains characters, the font area per character shall be no bigger than a quarter of that of the adopted name in China.


Chapter V Other Provisions

Article 28 For narcotic drugs, psychotropic substances, medicinal toxic drugs, radioactive pharmaceuticals, drugs for topical use, non-prescription drugs and other drugs having special marks specified by the State, their special marks shall be printed in the drug insert sheets and labels.
Where there are special provisions issued by the State for drug insert sheets and labels, they shall prevail.

Article 29 The labeling provisions for Chinese crude drugs and prepared slices of Chinese crude drugs shall be formulated separately by the State Food and Drug Administration.

Article 30 Where drug insert sheets and labels are not in compliance with the Provisions, a punishment shall be imposed in accordance with the relevant provisions of the Drug Administration Law of the People’s Republic of China.


Chapter VI Supplementary Provisions

Article 31 These Provisions shall come into force as of June 1, 2006. the Provisions for Drug Packaging, Labels and Insert Sheets (Provisional) issued by State Food and Drug Administration on October 15, 2005 shall be annulled therefrom.


中国人民银行关于调整黄金收售价格的补充通知

中国人民银行


中国人民银行关于调整黄金收售价格的补充通知
中国人民银行




中国人民银行各省、自治区、直辖市分行,深圳经济特区分行:
中国人民银行《关于调整黄金收售价格的通知》已发各分行,现将有关问题补充通知如下:
一、黄金收购价格:
含金量不足99.9%的,按每克80.50元收购;
含金量达99.9%以上的,按每克81.20元收购。
二、黄金配售价格:
含金量不足99.9%的,按每克82.10元配售;
含金量达99.9%以上的,按每克82.80元配售。
三、现行黄金联行调拨价不变。
四、调价前收购的黄金按原价上售;调价后收购的黄金要开立新的“收兑黄金”账户,待积存一定数量后,按实际收购价上售。
五、为了解这次调价前后黄金收购配售情况,各分行要认真填报2月份的金银收购配售量统计表(见附表),并于3月15日之前上报总行。
六、黄金收售价格调整后的账务处理,按银发[1993]259号、银发[1994]209号文件的有关规定执行。
七、新的黄金收售价格从1998年2月20日起执行。

附:中国人民银行 分行 月份 金银收购配售量统计表

---------------------------------------
| 黄 金 || 白 银
--|-----------------||-----------------
| 收 购 | 配 售 || 收 购 | 配 售
|--------|--------||--------|--------
调 |单价|纯重(克)|单价|纯重(克)||单价|纯重(克)|单价|纯重(克)
|--|-----|--|-----||--|-----|--|-----
价 |@ | |@ | ||@ | |@ |
|--|-----|--|-----||--|-----|--|-----
前 |@ | |@ | ||@ | |@ |
|--|-----|--|-----||--|-----|--|-----
|@ | |@ | ||@ | |@ |
--|--|-----|--|-----||--|-----|--|-----
小计| | | | || | | |
--|--|-----|--|-----||--|-----|--|-----
|单价|纯重(克)|单价|纯重(克)||单价|纯重(克)|单价|纯重(克)
调 |--|-----|--|-----||--|-----|--|-----
|@ | |@ | ||@ | |@ |
价 |--|-----|--|-----||--|-----|--|-----
|@ | |@ | ||@ | |@ |
后 |--|-----|--|-----||--|-----|--|-----
|@ | |@ | ||@ | |@ |
--|--|-----|--|-----||--|-----|--|-----
小计| | | | || | | |
--|--------|--------||--------|--------
合计| | || |
---------------------------------------
注:1.本表新旧价格合计收购量与新旧价格合计配售量要与分行当月金银
收付库存月报的收购数和配售数核对相符后再行填报;
2.本表于次月15日前上报总行。



1998年2月23日